bacterial flavoproteins Inhibitors
2 drugsAbout bacterial flavoproteins
Bacterial flavoproteins are enzymes using flavin cofactors (FAD or FMN) to catalyze redox reactions essential for bacterial metabolism. They are attractive drug targets due to their critical roles in bacterial processes, potentially allowing selective inhibition.
Bacterial flavoproteins are therapeutically relevant, though no genetic evidence directly links them to disease pathogenesis. The success of drugs targeting these enzymes underscores their importance as antibacterial targets.
Bacterial flavoproteins are targeted by two FDA-approved small molecule drugs: MACRODANTIN and MACROBID. These drugs, marketed by ALMATICA, are used to treat other indications.
Top bacterial flavoproteins Drugs
ALMATICA is the only company with approved drugs targeting bacterial flavoproteins.
Low competition may indicate high entry barriers or limited market potential for new entrants.
bacterial flavoproteins Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets bacterial flavoproteins, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer differentiation in this space.
bacterial flavoproteins Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on bacterial flavoproteins. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 | 100% |
| Phase 2 | 2 | 1 | 0 | 1 | 100% |
| Phase 3 | 6 | 3 | 1 | 2 | 75% |
| Phase 4 | 23 | 13 | 2 | 8 | 87% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
bacterial flavoproteins Drug Approval Timeline (1991 - 1991)
The first drug was approved in 1970, and the most recent in 1991, spanning 22 years.
The long gap since the last approval suggests a potential saturation or a need for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 29 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on bacterial flavoproteins. A trial counts if an approved drug acting on bacterial flavoproteins is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.